This experiment addresses the circadian clock dysfunction hypothesis that is currently absent from the AD hypothesis rankings but has strong mechanistic support. Circadian disruption impairs glymphatic clearance, metabolic coupling, and orexin signaling — creating a vicious cycle that accelerates amyloid-beta and tau accumulation. Unlike sleep-focused interventions that treat symptoms, this approach targets the upstream circadian master regulator.
Related: Circadian-Glymphatic-Metabolic Coupling Hypothesis | AD Knowledge Gaps | Sleep Disruption Experiment
Circadian clock dysfunction is a primary upstream driver of AD progression through:
Combined circadian restoration (light therapy + melatonin) + SWS enhancement (CBT-I + orexin modulation) will slow Aβ/tau accumulation more effectively than either alone.
Objective: Establish the relationship between circadian amplitude, glymphatic function, and AD biomarkers
Cohort: 800 participants
| Group | N | Characteristics |
|---|---|---|
| Early AD (CDR 0.5) | 250 | Biomarker-confirmed |
| MCI | 250 | CDR 0.5, no dementia |
| Cognitively normal | 150 | Age-matched controls |
| Circadian disorder | 150 | Sleep phase disorder, no cognitive symptoms |
Measures:
Analysis: Circadian amplitude (circadian rhythm index) vs. glymphatic metrics vs. biomarker change rate.
Objective: Test whether restoring circadian amplitude slows biomarker progression
Design: Randomized, sham-controlled, 2x2 factorial
| Arm | Circadian | Sleep |
|---|---|---|
| A | Active light therapy + melatonin (morning bright light, evening melatonin 0.5mg) | Active CBT-I |
| B | Active light therapy + melatonin | Sleep hygiene (control) |
| C | Sham light + placebo melatonin | Active CBT-I |
| D | Sham light + placebo melatonin | Sleep hygiene (control) |
Sample: n=300 prodromal AD / early AD (CDR 0.5-1)
Duration: 18 months
Primary endpoint: Change in plasma p-tau217 from baseline
Secondary: CSF Aβ42/40, tau PET SUVr, hippocampal volume, cognitive scores, ALPS index
Mechanism: Active circadian intervention is expected to increase SWS fraction by 20-30% and improve glymphatic clearance efficiency by 40-60% (based on prior circadian + sleep studies).
Objective: Test adjunctive orexin agonism and direct glymphatic enhancement
Design: Open-label, adaptive
Cohort: n=100 non-responders or partial responders from Phase 2
Arms:
Endpoints: Glymphatic ALPS index, CSF Aβ42/40, overnight Aβ oscillation amplitude
Objective: Validate clock-glymphatic-metabolic coupling in human tissue and preclinical models
Models:
Endpoints: Aβ42 accumulation rate, glymphatic tracer clearance, metabolic flexibility assay
| Dimension | Score | Rationale |
|---|---|---|
| Technical | 8/10 | Actigraphy, MRI-ALPS, plasma biomarkers standard; clock gene assays established |
| Timeline | 6/10 | 42 months total; requires multi-center coordination for circadian standardization |
| Cost | 4/10 | Estimated $12-15M total; MRI-ALPS expensive at scale |
| Interpretability | 8/10 | Direct biomarker readouts; circadian metrics quantifiable |
| Clinical Relevance | 9/10 | Circadian dysfunction is highly prevalent and addressable |
| Phase | Cost |
|---|---|
| Phase 1 (Biomarker) | $2.5M |
| Phase 2 (Intervention) | $5.0M |
| Phase 3 (Orexin+tFUS) | $3.0M |
| Phase 4 (Mechanistic) | $2.0M |
| Total | $12.5M |